FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3003884964> ?p ?o ?g. }

• W3003884964 endingPage "1459" @default.
• W3003884964 startingPage "1448" @default.
• W3003884964 abstract "Background Nilotinib is a potent, second‐generation inhibitor of BCR ‐ABL1 tyrosine kinase and has been approved as frontline and salvage therapy for patients with chronic‐phase chronic myeloid leukemia (CP‐CML). Methods In this single‐institution, phase 2 study, 122 patients with newly diagnosed CP‐CML received nilotinib 400 mg twice daily. The median follow‐up on study was 78.3 months (interquartile range, 58.4‐96.5 months). Results Fifty‐six percent of patients remained on therapy at the last follow‐up. Both the complete cytogenetic response rate and the major molecular response (MR) rate were 91%. Seventy‐five percent and 59% of patients achieved a ≥4.5‐log reduction in BCR‐ABL1 transcripts (MR4.5) and a sustained MR4.5 beyond 2 years, respectively. The estimated event‐free survival and overall survival rates at 5 years were 89% and 93%, respectively, and the corresponding rates at 10 years were 85% and 88%, respectively. Treatment discontinuation due to toxicity occurred in 19% of patients, mostly because of cardiovascular events (10%) and biochemical abnormalities (6%). The top 3 nonhematologic toxicities were rash (55%), elevated bilirubin (57%), and elevated aminotransferases (48%). Hematologic toxicity was transient and mild. Ischemic cardiovascular adverse events occurred in 8% of patients. Four patients (3%) progressed to accelerated or blast phase while on therapy, and 7 patients (6%) died on study. Conclusions The current data confirm the long‐term efficacy of nilotinib 400 mg twice daily in patients with CP‐CML. A majority of patients can achieve sustained MR4.5." @default.
• W3003884964 created "2020-02-07" @default.
• W3003884964 creator A5009582343 @default.
• W3003884964 creator A5010663972 @default.
• W3003884964 creator A5011548707 @default.
• W3003884964 creator A5015140142 @default.
• W3003884964 creator A5018403822 @default.
• W3003884964 creator A5020340537 @default.
• W3003884964 creator A5022647201 @default.
• W3003884964 creator A5028845635 @default.
• W3003884964 creator A5045902951 @default.
• W3003884964 creator A5049385583 @default.
• W3003884964 creator A5055045706 @default.
• W3003884964 creator A5061026876 @default.
• W3003884964 creator A5080350639 @default.
• W3003884964 creator A5084290698 @default.
• W3003884964 creator A5085521139 @default.
• W3003884964 creator A5090435894 @default.
• W3003884964 date "2020-01-30" @default.
• W3003884964 modified "2023-10-18" @default.
• W3003884964 title "Long‐term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic‐phase chronic myeloid leukemia" @default.
• W3003884964 cites W1703585081 @default.
• W3003884964 cites W1968747503 @default.
• W3003884964 cites W2039978091 @default.
• W3003884964 cites W2061440903 @default.
• W3003884964 cites W2072834954 @default.
• W3003884964 cites W2085342571 @default.
• W3003884964 cites W2097946794 @default.
• W3003884964 cites W2099153775 @default.
• W3003884964 cites W2112810605 @default.
• W3003884964 cites W2124196948 @default.
• W3003884964 cites W2143939343 @default.
• W3003884964 cites W2146658081 @default.
• W3003884964 cites W2151486690 @default.
• W3003884964 cites W2260921597 @default.
• W3003884964 cites W2560342075 @default.
• W3003884964 cites W2590307110 @default.
• W3003884964 cites W2790692615 @default.
• W3003884964 doi "https://doi.org/10.1002/cncr.32623" @default.
• W3003884964 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31999850" @default.
• W3003884964 hasPublicationYear "2020" @default.
• W3003884964 type Work @default.
• W3003884964 sameAs 3003884964 @default.
• W3003884964 citedByCount "13" @default.
• W3003884964 countsByYear W30038849642020 @default.
• W3003884964 countsByYear W30038849642021 @default.
• W3003884964 countsByYear W30038849642022 @default.
• W3003884964 countsByYear W30038849642023 @default.
• W3003884964 crossrefType "journal-article" @default.
• W3003884964 hasAuthorship W3003884964A5009582343 @default.
• W3003884964 hasAuthorship W3003884964A5010663972 @default.
• W3003884964 hasAuthorship W3003884964A5011548707 @default.
• W3003884964 hasAuthorship W3003884964A5015140142 @default.
• W3003884964 hasAuthorship W3003884964A5018403822 @default.
• W3003884964 hasAuthorship W3003884964A5020340537 @default.
• W3003884964 hasAuthorship W3003884964A5022647201 @default.
• W3003884964 hasAuthorship W3003884964A5028845635 @default.
• W3003884964 hasAuthorship W3003884964A5045902951 @default.
• W3003884964 hasAuthorship W3003884964A5049385583 @default.
• W3003884964 hasAuthorship W3003884964A5055045706 @default.
• W3003884964 hasAuthorship W3003884964A5061026876 @default.
• W3003884964 hasAuthorship W3003884964A5080350639 @default.
• W3003884964 hasAuthorship W3003884964A5084290698 @default.
• W3003884964 hasAuthorship W3003884964A5085521139 @default.
• W3003884964 hasAuthorship W3003884964A5090435894 @default.
• W3003884964 hasBestOaLocation W30038849641 @default.
• W3003884964 hasConcept C119060515 @default.
• W3003884964 hasConcept C126322002 @default.
• W3003884964 hasConcept C141071460 @default.
• W3003884964 hasConcept C197934379 @default.
• W3003884964 hasConcept C2777413986 @default.
• W3003884964 hasConcept C2777583451 @default.
• W3003884964 hasConcept C2778570526 @default.
• W3003884964 hasConcept C2778715236 @default.
• W3003884964 hasConcept C2778729363 @default.
• W3003884964 hasConcept C3019892230 @default.
• W3003884964 hasConcept C71924100 @default.
• W3003884964 hasConcept C90924648 @default.
• W3003884964 hasConceptScore W3003884964C119060515 @default.
• W3003884964 hasConceptScore W3003884964C126322002 @default.
• W3003884964 hasConceptScore W3003884964C141071460 @default.
• W3003884964 hasConceptScore W3003884964C197934379 @default.
• W3003884964 hasConceptScore W3003884964C2777413986 @default.
• W3003884964 hasConceptScore W3003884964C2777583451 @default.
• W3003884964 hasConceptScore W3003884964C2778570526 @default.
• W3003884964 hasConceptScore W3003884964C2778715236 @default.
• W3003884964 hasConceptScore W3003884964C2778729363 @default.
• W3003884964 hasConceptScore W3003884964C3019892230 @default.
• W3003884964 hasConceptScore W3003884964C71924100 @default.
• W3003884964 hasConceptScore W3003884964C90924648 @default.
• W3003884964 hasFunder F4320332161 @default.
• W3003884964 hasFunder F4320332521 @default.
• W3003884964 hasFunder F4320337351 @default.
• W3003884964 hasIssue "7" @default.
• W3003884964 hasLocation W30038849641 @default.
• W3003884964 hasLocation W30038849642 @default.
• W3003884964 hasOpenAccess W3003884964 @default.
• W3003884964 hasPrimaryLocation W30038849641 @default.

• next